What Novo Nordisk's Catalent purchase means for Bloomington, Indiana
The parent company of Danish drug maker Novo Nordisk plans to buy Catalent, including the Bloomington operations, for $16.5 billion. Novo Holdings and Catalent announced the plan Monday and said they hope to conclude the deal by the end of the year. The plan has generated some unease among…
#danish #novonordisk #bloomington #novoholdings #catalent #novo #wegovycatalent #jenpearl #indianauniversity #georgetelthorst